Skip to content

US · NTLA · BIOTECHNOLOGY

Intellia Therapeutics, Inc. (NTLA) intrinsic value and stock valuation

$10.00as of 2026-11-21 · Mkt cap 1.23B

Data updated · price as of 2026-11-21

Fairly valuedIC value is within 20% of the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Intellia Therapeutics, Inc. DCF and intrinsic value

InvestorsCraft values NTLA with the Chepakovich two-stage DCF model — currently rated fairly valued. How the model works · Run your own DCF prefilled from NTLA’s statements →

Intellia Therapeutics, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Cambridge, MA 02139 intelliatx.com

How the business is doing

Fiscal 2014–2025, USD

Revenue
$67.7M+3.1% 5y CAGRd
20142025
Net income
-$-412.69M
20142025
Free cash flow
-$-354.66M
20142025
Total equity
$671.4M+5% 5y CAGRd
20142025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2014–2025, USD
20252024202320222021
Revenue$67.7M$57.9M$36.3M$52.1M$33.1M
Operating income-$-440.99M-$-534.26M-$-515.29M-$-458.16M-$-267.85M
Net income-$-412.69M-$-519.02M-$-481.19M-$-474.19M-$-267.89M
EPSd-$-3.81M-$-5.25M-$-5.42M-$-6.16M-$-3.78M
Operating cash flow-$-348.88M-$-348.88M-$-394.09M-$-333.29M-$-225.03M
Capital expenditure-$-5.78M-$-5.78M-$-13.98M-$-58.39M-$-12.76M
Free cash flow-$-354.66M-$-354.66M-$-408.07M-$-391.68M-$-237.79M
Total assets$842.1M$1.19B$1.3B$1.52B$1.29B
Total debt$93.3M$210.2M$115.4M$130.7M$74M
Net debt-$-62.13M$21M-$-111.4M-$-392.8M-$-49.38M
Total equity$671.4M$872M$1.05B$1.24B$1.04B
Cash and short-term investments$449.9M$601.5M$912.2M$1.19B$748.7M
Income statement
20252024202320222021
Revenue$67.7M$57.9M$36.3M$52.1M$33.1M
Cost of revenue$15.9M$10.3M$8.98M$7.57M$6.89M
Gross profit$51.8M$47.6M$27.3M$44.6M$26.2M
Research and development expenses$388.9M$466.3M$435.1M$420M$229.8M
Selling, general and administrative expenses$119.8M$125.8M$116.5M$90.3M$71.1M
Other expenses-$-15.92M-$-10.29M-$-8.98M-$-7.57M-$-6.89M
Operating expenses$492.7M$581.9M$542.6M$502.7M$294M
Cost and expenses$508.7M$592.1M$551.6M$510.3M$300.9M
Interest income$29.2M$47.8M$49.8M$8.54M$1.28M
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$15.9M$10.3M$8.98M$7.57M$6.89M
Ebitda-$-396.77M-$-508.74M-$-472.22M-$-466.61M-$-261M
Operating income-$-440.99M-$-534.26M-$-515.29M-$-458.16M-$-267.85M
Total other income/expenses, net$28.3M$15.2M$34.1M-$-16.02M-$-40K
Income before tax-$-412.69M-$-519.02M-$-481.19M-$-474.19M-$-267.89M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-412.69M-$-519.02M-$-481.19M-$-474.19M-$-267.89M
Weighted average shares outstanding$108.4M$98.9M$88.8M$77M$70.9M
Weighted average diluted shares outstanding$108.4M$98.9M$88.8M$77M$70.9M
Balance sheet
20252024202320222021
Cash and short-term investments$449.9M$601.5M$912.2M$1.19B$748.7M
Net receivables$9.47M$8.52M$36.5M$3.77M$2.03M
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$527.7M$639.9M$998.3M$1.22B$769.3M
Property, plant and equipment, net$123.6M$246.7M$148.1M$161M$100.1M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$35.5M$44.3M$154.5M$142.3M$425.1M
Total non-current assets$314.4M$551.2M$302.7M$303.3M$525.2M
Total assets$842.1M$1.19B$1.3B$1.52B$1.29B
Accounts payable$20.3M$14.6M$7.45M$5.15M$9.65M
Short-term debt$26.5M$20.3M$18.6M$16.7M$9.11M
Deferred revenue$7.29M$20.7M$22.1M$43.8M$63.8M
Total current liabilities$103.9M$110.9M$115.2M$126.6M$125.8M
Long-term debt$66.9M$190M$96.8M$114M$64.9M
Deferred revenue, non-current$0.00$18.3M$38.9M$19.9M$63.5M
Total non-current liabilities$66.9M$208.2M$135.6M$158M$128.4M
Capital lease obligations$26.5M$210.2M$115.4M$130.7M$74M
Total liabilities$170.7M$319.1M$250.8M$284.5M$254.2M
Common stock$10K$10K$10K$10K$10K
Retained earnings-$-2.59B-$-2.18B-$-1.66B-$-1.18B-$-703M
Accumulated other comprehensive income (loss)$1.03M$600K-$-2.26M-$-7.46M-$-2.63M
Total equity$671.4M$872M$1.05B$1.24B$1.04B
Total investments$330M$456.6M$840M$811.4M$1.05B
Total debt$93.3M$210.2M$115.4M$130.7M$74M
Net debt-$-62.13M$21M-$-111.4M-$-392.8M-$-49.38M
Cash flow statement
20252024202320222021
Net income-$-519.02M-$-519.02M-$-481.19M-$-474.19M-$-267.89M
Depreciation and amortization$10.3M$10.3M$8.98M$7.57M$6.89M
Stock-based compensation$154.3M$154.3M$134.1M$91.4M$47M
Change in working capital-$-73.75M$11.9M-$-52.45M-$-53.87M-$-22.9M
Accounts receivable-$-950K$27.9M-$-32.69M-$-1.74M$100K
Inventory$0.00$0.00$0.00$0.00$7.82M
Accounts payable$5.99M$6.8M$2.52M-$-4.58M$530K
Net cash provided by operating activities-$-348.88M-$-348.88M-$-394.09M-$-333.29M-$-225.03M
Investments in property, plant and equipment-$-5.78M-$-5.78M-$-13.98M-$-58.39M-$-12.76M
Acquisitions, net$0.00$0.00$0.00-$-44.68M-$-3M
Net cash used for investing activities$125.6M$125.6M-$-31.35M$160.3M-$-550.78M
Common stock issued$131.5M$176.9M$119.8M$565.8M$693.6M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$185.8M$185.8M$130.3M$583M$736.7M
Net change in cash-$-37.57M-$-37.57M-$-295.11M$410M-$-39.12M
Cash at end of period$202.8M$202.8M$240.4M$535.5M$125.5M
Operating cash flow-$-348.88M-$-348.88M-$-394.09M-$-333.29M-$-225.03M
Capital expenditure-$-5.78M-$-5.78M-$-13.98M-$-58.39M-$-12.76M
Free cash flow-$-354.66M-$-354.66M-$-408.07M-$-391.68M-$-237.79M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Intellia Therapeutics, Inc.

        Intellia Therapeutics, Inc. is a biotechnology firm dedicated to advancing therapeutic treatments through its expertise in genome editing. The company's pipeline includes several in vivo (administered within the body) programs. NTLA-2001 is currently undergoing a Phase 1 clinical trial for transthyretin amyloidosis, while NTLA-2002 targets hereditary angioedema. Additionally, Intellia is developing various other liver-focused therapies for conditions such as hemophilia A and B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo (processed outside the body) pipeline features NTLA-5001, a candidate for acute myeloid leukemia. The company is also progressing proprietary programs focused on creating engineered cell therapies to address diverse oncological and autoimmune disorders. At the core of Intellia's technology is the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has established multiple licensing and collaboration agreements. These include a partnership with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for treating sickle cell disease, and a co-development agreement with Regeneron Pharmaceuticals, Inc. for potential products against hemophilia A and B. The company also collaborates with Ospedale San Raffaele and holds a strategic alliance with SparingVision SAS to develop novel genomic medicines for ocular diseases, leveraging CRISPR/Cas9 technology. The company, initially known as AZRN, Inc., was founded in 2014 and operates from its headquarters in Cambridge, Massachusetts.

        CEO
        John Leonard
        Employees
        377
        Beta
        1.77

        Explore

        Frequently asked questions

        What is the intrinsic value of Intellia Therapeutics, Inc. (NTLA)?

        Intellia Therapeutics, Inc. (NTLA) is currently fairly valued based on the InvestorsCraft IC model — IC value is within 20% of the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is NTLA undervalued?

        NTLA trades at a price of $10.00 (Nov 21, 2026): fairly valued — IC value is within 20% of the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.